Silence Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Silence Therapeutics Stock Forecast and Price Target
Year-long price target forecasts from prominent analysts have recently been released for Silence Therapeutics, with an average price target of $50.00. This potential gain of 133.43 percent from the previous closing price in May, 2024 is calculated on a high forecast of $75.00 and a low estimate of $42.00. Although you may not be interested in SLN stock, you should still be aware of its competitors.
133.43% Upside
Silence Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Silence Therapeutics's Price has grown, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $22.75 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GWPH Stock Forecast | GW Pharmaceuticals | - |
6
|
$219.00 | Buy/Sell | $188.33 | 5.14% |
| ABCM Stock Forecast | Abcam | - |
18
|
$23.99 | Buy/Sell | $19.25 | -67.15% |
| GNS Stock Forecast | Genus | Buy |
18
|
£17.36 | Buy/Sell | £33.09 | 58.41% |
| AUTL Stock Forecast | Autolus Therapeutics | Buy |
6
|
$4.00 | Buy/Sell | $9.23 | 175.00% |
| BCYC Stock Forecast | Bicycle Therapeutics | Outperform |
7
|
$24.20 | Buy/Sell | $44.47 | 77.69% |
Silence Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Silence Therapeutics's Revenue has grown, rising from $5.48M to $17.50M – a growth of 219.34%. In the next year, analysts believe that Revenue will reach $20.55M – an increase of 17.43%. For the next seven years, the forecast is for Revenue to grow by 411.85%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CMPS Stock Forecast | COMPASS Pathways | Buy |
3
|
$8.48 | Buy/Sell | $45.43 | 224.29% |
| MREO Stock Forecast | Mereo BioPharma Group | Buy |
5
|
$3.15 | Buy/Sell | $3.46 | 51.43% |
| ADAP Stock Forecast | Adaptimmune Therapeutics | Outperform |
7
|
$1.21 | Buy/Sell | $3.60 | 106.61% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ORTX Stock Forecast | Orchard Therapeutics | - |
7
|
$16.70 | Buy/Sell | $16.00 | -100.00% |
| OXB Stock Forecast | Oxford Biomedica | Outperform |
10
|
£2.87 | Buy/Sell | £4.24 | 36.93% |
| BVXP Stock Forecast | Bioventix PLC |
18
|
£43.25 | Buy/Sell | £44.00 | 36.42% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NIOX Stock Forecast | NIOX Group Plc | Buy |
6
|
£0.70 | Buy/Sell | £0.76 | 10.00% |
| HZD Stock Forecast | Horizon Discovery Group | - |
3
|
£0.00 | Buy/Sell | £0.00 | 0.00% |
| ETX Stock Forecast | e-therapeutics |
9
|
£0.16 | Buy/Sell | £0.16 | -100.00% |
Silence Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Silence Therapeutics's EBITDA has grown by 57.42%, rising from $-30.67M to $-48.28M. For the next year, analysts predict that EBITDA will reach $-60.37M – an increase of 25.04%. Over the next seven years, experts believe that Silence Therapeutics's EBITDA will grow at a rate of 53.44%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AGY Stock Forecast | Allergy Therapeutics | - |
12
|
£0.03 | Buy/Sell | £0.50 | -100.00% |
| SCLP Stock Forecast | Scancell Holdings | Buy |
4
|
£0.09 | Buy/Sell | £0.23 | 155.56% |
| BRNS Stock Forecast | Barinthus Biotherapeutics | Outperform |
2
|
$2.05 | Buy/Sell | $8.80 | 241.46% |
Silence Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Silence Therapeutics's EBIT has grown, moving from $-30.98M to $-48.59M – an increase of 56.84%. In the next year, analysts predict that EBIT will jump to $-50.88M – up 4.71% from the current level. According to professionals, by 2030, Silence Therapeutics's EBIT will have decreased by 359.31%, falling down to $126.00M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REDX Stock Forecast | Redx Pharma Plc | Buy |
9
|
£0.15 | Buy/Sell | £1.25 | 766.67% |
| NANO Stock Forecast | Nanoco Group |
8
|
£0.19 | Buy/Sell | £0.09 | 215.79% | |
| DNL Stock Forecast | Diurnal Group | - |
0
|
£0.27 | Buy/Sell | £0.69 | -100.00% |
Silence Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Silence Therapeutics's EPS has grown, rising from $-1.64 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $-0.94 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TLSA Stock Forecast | Tiziana Life Sciences Ltd | Buy |
2
|
$0.52 | Buy/Sell | $5.00 | 363.46% |
| TRX Stock Forecast | Tissue Regenix Group |
5
|
£0.62 | Buy/Sell | £1.20 | 93.55% | |
| OKYO Stock Forecast | OKYO Pharma | Outperform |
0
|
$1.50 | Buy/Sell | $4.00 | 366.67% |
.jpg)